General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

The Malaria Initiative

The Novartis Malaria Initiative focuses on improving access to treatment, helping communities in malaria-endemic countries deliver better healthcare and investing in research and development into the next generation of antimalarials. Over the past decade, the initiative has become one of the largest access-to-medicine programs in the healthcare industry, measured by the number of patients reached annually.

Since 2001, working with a range of organizations, we have provided more than 700 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children. We are proud of the remarkable public health milestones these collaborations have helped to achieve.

Innovative collaboration starts between Novartis and Chinese partners
Daniel Vasella, Honorary Chairman of the Board of Novartis, commits to make the fight against malaria a key aspect of the company’s access-to-medicine programs
First regulatory approvals for artemether-lumefantrine in Africa (Gabon), Switzerland and Europe (UK)
Launch of artemether-lumefantrine, the first ACT brought to market in a fixed-dose form
Collaboration with the WHO to supply artemether-lumefantrine without profit to the public sector
Artemether-lumefantrine is the first ACT listed on the WHO's Model List of Essential Medicines
Subsequent production scale-up to 100 million treatment capacity per year
Start of best practice sharing workshops with national malaria control program managers
Price more than halved thanks to economies of scale
Healthcare Compliance Packaging Council Award
  • Launch of Dispersible artemether-lumefantrine with MMV
  • Artemether-lumefantrine is the first ACT approved by the US FDA
  • Prix Galien USA
  • World Business and Development Award, United Nations
  • Award for Corporate Social Responsibility by the Association of Strategic Alliance Professionals
Wall Street Journal Technology Innovation Award for SMS for Life
GBC Business Action on Health Awards for SMS for Life
SMS for Life honored with a catalytic grant from The Innovation Working Group and the Wall Street Journal’s Technology Innovation Award in the Health-Care IT category
New private-sector access program launched to make high-quality antimalarials affordable to patients in malaria-endemic countries
Novartis joins forces with Malaria No More on the Power of One campaign. Malaria No More honors Novartis with first annual Malaria Award for Private Sector Excellence and with Global Corporate Citizenship Award
600 million Novartis ACT treatments delivered without profit to patients since 2001, of which 200 million dispersible pediatric treatments since 2009
Two completely new antimalarial compounds move into development and a third new malaria drug target is discovered